Research
Energy balance
The treatment with GLP-1 RA resulted in a reduction in the risk of any cardiovascular event with a relative risk of 0.81.
The relative risk indicates a significant benefit of GLP-1 RA in reducing cardiovascular events.
StrongSupportsmedium confidence
Treatment with GLP-1 RA versus placebo resulted in a reduction in the risk of any cardiovascular event (RR = 0.81, CI 0.70-0.92; p = .001).
Why this rating
Based on a meta-analysis of placebo-controlled randomized controlled trials.
Source
Effect of glucagon‐like peptide‐1 receptor agonists on cardiovascular events in overweight or obese adults without diabetes: A meta‐analysis of placebo‐controlled randomized trials
Ana Rita Leite et al. · Diabetes Obesity and Metabolism · 2022
Meta-analysisCited 34×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →